Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04958265 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

Study acronym: COMMUTE-p
StatusActive, Not Recruiting
PhasePhase 3
Started2021-11-17
View on ClinicalTrials.gov ↗
This study aims to evaluate the efficacy and safety of crovalimab in pediatric participants with aHUS.

Amendment history 2 changes detected by DataLookout

2026-09-10
Primary endpoint(s) modified
WasPercentage of Participants with complete TMA response (cTMAr) (Naive Cohort only)
NowNaïve Cohort: Percentage of Participants With Complete Thrombotic Microangiopathy Response (cTMAr) Anytime From Baseline to Week 25 (After 24 Weeks on Treatment)
2026-09-10
Results posted: 2026-09-09
Trial Details
NCT Number NCT04958265
Lead Sponsor Hoffmann-La Roche
Collaborators: Chugai Pharmaceutical
Conditions Atypical Hemolytic Uremic Syndrome
Enrollment 41 participants
Start Date 2021-11-17
Primary Completion 2025-07-04 (estimated)
Study Completion 2029-05-19 (estimated)
Updated on ClinicalTrials.gov 2026-09-09